A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.
Inclusion Criteria:
Meets one of the following:
Participants with history of an ASCVD event: Participants ≥ 18 years of age at the time of signing the ICF with a history of MI or ischaemic stroke suspected to be due to atherosclerotic vascular disease ≥ 1 month prior to randomisation (presumed lacunar or cardioembolic strokes are not qualifying events), or revascularisation for symptomatic lower limb PAD any time prior to screening
Additional risk factors based on the level of the LDL-C and timing of MI or stroke:
o Participants with an LDL-C ≥ 75 mg/dL (≥ 1.9 mmol/L) need to have at least one of the other additional risk factors (i to viii) below.
ii) T2DM requiring ongoing medical therapy iii) Age ≥ 65 years v) Previous above ankle amputation due to PAD vi) Previous diagnosis of non-end stage CKD
Participants at increased risk of a first ASCVD event: Male participant ≥ 50 years of age or female participant ≥ 55 years of age at the time of signing the ICF with LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L), with no prior history of MI, ischaemic stroke due to atherosclerotic disease, or leg revascularisation for symptomatic lower limb PAD, and with diagnostic evidence of at least one of the following disease categories (i, ii, or iii):
(i) Significant atherosclerotic artery disease (ii) High-risk Type 1 or Type 2 diabetes mellitus with manifestation of at least one of the following end-organ diseases:
Nephropathy - Persistent (≥ 2 readings) microalbuminuria (urine albumin/creatinine ratio ≥ 30 mg/g) and/or persistent eGFR < 60 mL/min/1.73 m2. At least one reading must come from the medical record within the last 12 months in addition to the reading from screening
Retinopathy - Treated diabetic retinopathy (surgical intervention or injectable therapy) or prior diagnosis made by a relevant healthcare specialist
Neuropathy - Treated neuropathy (medical therapy for pain relief or symptom alleviation) or prior diagnosis made by a relevant healthcare specialist
ABI < 0.9 or > 1.4 - confirmed either in study during screening or randomisation, or from the medical record within the last 5 years (iii) Documented atherosclerosis of less significance
For (ii) and (iii), participants need to have at least one of the additional risk factors below:
Participants should receive a background lipid lowering regimen anticipated to achieve at least a ~50% reduction in LDL-C. Except in cases of intolerance, the regimen should include a high intensity statin therapy or lower intensity statin therapy in combination with an oral agent with proven outcome benefit (eg, ezetimibe and/or bempedoic acid).
Participants must achieve a stable background lipid lowering therapy > 28 days before screening.
Exclusion criteria:
Any underlying known disease, or condition including homozygous familial hypercholesterolaemia, or LDL or plasma apheresis within 12 months prior to randomisation, that, in the opinion of the investigator, might interfere with the interpretation of the clinical study results.
Any revascularisation procedure planned within the next 3 months.
Available imaging assessment within the last 3 years showing either coronary calcium score of zero, or a coronary computed tomography angiography with no atherosclerosis.
Calculated eGFR < 15 mL /min/1.73 m2 at screening.
Any laboratory values with the following deviations at screening:
Uncontrolled T2DM defined as HbA1c ≥ 9.5% at screening.
Inadequately treated hypothyroidism defined as TSH > 1.5 × ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening.
Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months of screening or planned use during the study.
Use of gemfibrozil within one week prior to the Screening Visit or planned use during the study.
Use of PCSK9 inhibitors: evolocumab/alirocumab within 12 weeks of the Screening Visit or planned use during the study, or inclisiran within 18 months of the Screening Visit or planned use during the study, or any other approved PCSK9 inhibitor use within 5 half lives prior to the Screening Visit or planned use during the study.
information.center@astrazeneca.com1-877-240-9479
CABA, C1025ABI, Argentina
CABA, C1426, Argentina
Capital Federal, C1014A, Argentina
Ciudad Autonoma de Bs As, C1023AAB, Argentina
Ciudad de Buenos Aires, 1128, Argentina
Ciudad de Buenos Aires, C1019ABS, Argentina
Ciudad de Buenos Aires, C1094AAD, Argentina
Ciudad de Buenos Aires, C1425AGC, Argentina
Ciudad de Buenos Aires, C1428DCO, Argentina
Ciudad de Rosario, S2000, Argentina
Nueva Córdoba, X5000JJS, Argentina
North York, Ontario M6B 3H7, Canada
North York, Ontario M9N 1W4, Canada
Region Metropolitana, 7550000, Chile
Huaian, 223300, China
Jinzhou Shi, 121001, China
Shaoguan Shi, 512025, China
Taian, 271099, China
Ostrava-Dubina, 700 30, Czechia
Pribram VIII, 261 01, Czechia
Saint-Priez En Jarez, 42270, France
Bad Friedrichshall, 47177, Germany
Karlsbad, 76307, Germany
Mainz A. Rhein, 55131, Germany
Mühldorf A. Inn, 84453, Germany
Rotenburg A.d. Fulda, 36199, Germany
Rüdersdorf B. Berlin, 15562, Germany
Heraklio, 71110, Greece
Nyíregyháza-Sóstóhegy, 4481, Hungary
Hydarabad, 500055, India
New Dehli, 110001, India
Ami-machi, 300-1155, Japan
Asahi-shi, 289-2511, Japan
Asahikawa-shi, 070-8530, Japan
Chiyoda-ku, 101-0062, Japan
Chiyoda-ku, 101-8643, Japan
Fujisawa-shi, 251-0041, Japan
Fujisawa-shi, 251-8550, Japan
Funabashi-shi, 273-8588, Japan
Hamada-shi, 697-8511, Japan
Higashiyamato-shi, 207-0014, Japan
Ichikawa-shi, 272-8516, Japan
Itabashi-ku, 173-8610, Japan
Izunokuni-shi, 410-2295, Japan
Kakegawa-shi, 436-8555, Japan
Kanoya-shi, 893-0015, Japan
Kashiwara-shi, 582-0005, Japan
Kasuga-shi, 816-0864, Japan
Kasuya-gun, 811-2310, Japan
Kawasaki-shi, 215-0026, Japan
Kishiwada-shi, 596-0042, Japan
Koga-shi, 811-3195, Japan
Komatsu-shi, 923-8560, Japan
Komatsushima-shi, 773-8502, Japan
Kumagaya-shi, 360-0197, Japan
Kurashiki-shi, 710-8602, Japan
Kure-shi, 737-0023, Japan
Machida-shi, 194-0023, Japan
Minokamo Shi, 505-8510, Japan
Miyakonojo-shi, 885-0035, Japan
Nakagami-gun, 901-2393, Japan
Nerima-ku, 176-8530, Japan
Nishinomiya-shi, 663-8241, Japan
Omura-shi, 856-0021, Japan
Omura-shi, 856-8562, Japan
Saitama-shi, 338-0837, Japan
Shinjuku-ku, 160-0004, Japan
Suita-shi, 564-8565, Japan
Suwa-shi, 392-8510, Japan
Suzuka-shi, 513-8630, Japan
Tachikawa-shi, 190-0014, Japan
Takatsuki-shi, 569-8686, Japan
Tanabe-shi, 646-8558, Japan
Toride-shi, 302-0022, Japan
Urasoe-Shi, 901-2102, Japan
Urayasu-shi, 279-0021, Japan
Ureshino-shi, 843-0393, Japan
Ushiku-shi, 300-1207, Japan
Wako-shi, 351-0102, Japan
Sarawak Miri, 98000, Malaysia
Ebdentown, 5018, New Zealand
Hutt Central, 5010, New Zealand
Palmerston North Central, 4414, New Zealand
Waikato, 3204, New Zealand
Wanchac, 8002, Peru
Manadaluyong City, 1552, Philippines
Middelbrug, 1029, South Africa
Changwon-si, 51139, South Korea
Banphaeo, 74120, Thailand
Klong Luang, 12120, Thailand
Mueang, 20000, Thailand
Hochiminh, 700000, Vietnam
Hochiminh, 70000, Vietnam
Hồ Chí Minh, 9000, Vietnam